Seeking Alpha

Investorideas.com's  Instablog

Investorideas.com
Send Message
www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas, news and research for biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on... More
My company:
Investor Ideas
My blog:
Investor Ideas Newswire
View Investorideas.com's Instablogs on:
  • Q&A Interview with CEO of BioSante Pharmaceuticals (NasdaqGM: BPAX) Following News of Positive LibiGel® Safety Data Review in Phase III Program
    Q&A Interview with CEO of BioSante Pharmaceuticals (NasdaqGM: BPAX) Following News of Positive LibiGel® Safety Data Review in Phase III Program
     
    Stephen M. Simes, President and CEO of BioSante Shares How BioSante is Closer to Capturing the Female Libido Drug Market
     
     
    Point Roberts, WA- October 24, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an exclusive Q&A with Mr. Stephen M. Simes, President and Chief Executive Officer ofBioSante Pharmaceuticals, Inc. (NasdaqGM: BPAX ).
     
    The Company reported news earlier this month of positive LibiGel® safety data review in the Phase III program. Mr. Simes explains the significance of the data and what’s next to take 
    LibiGel (testosterone gel) to market for the millions of women anxiously awaiting an approved FDA solution for female sexual dysfunction.  
     
    BioSante Pharmaceuticals Interview
     
    Q: Investorideas.com
    In the Company’s last release, it was reported that“The DMC once again has recommended that the safety study continue as per the FDA-agreed protocol, without modification as there were no general or specific safety issues based on their unblinded review of adverse events.”
    Based on competitors dropping out of the market due to lack of sufficient safety data how significant is it that BioSante has reached this stage?
     
    A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
    Very significant. BioSante is conducting the largest safety study ever undertaken for a drug in the treatment of female sexual dysfunction. We are in the fourth year of a cardiovascular event and breast cancer safety study having completed enrollment at 3,656 women equally randomized to LibiGel or placebo.   The Independent data monitoring committee has recommended continuing the study as per FDA-agreed protocol based on their seventh unblinded review of all safety data. We expect to be able to demonstrate the safety of LibiGel for the treatment of female sexual dysfunction.
     
    Q: Investorideas.com
    Can you explain to investors the next steps prior to filing an NDA in 2012?
     
    A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
    We now have completed two LibiGel Phase III efficacy trials of over 500 women each. We expect to announce top-line efficacy data in December of this year. The LibiGel safety study will undergo its primary safety analysis next summer which will put us in position to submit the new drug application (NDA) by the end of 2012. Bases on positive safety and efficacy data we hope to receive FDA approval by mid-2013.
     
    Q: Investorideas.com
    LibiGel is currently the only product in Phase III clinical development for the treatment of female sexual dysfunction (NYSE:FSD), specifically hypoactive sexual desire disorder (HSDD), with an estimated market of $2 billion. How does the Company see the revenue stream following FDA approval?
     
    A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
    We expect that the market for the treatment of female sexual dysfunction will be over $2 billion, which is the size of the erectile dysfunction market in the U.S. Based on published reports we believe the market for FSD will be at least that large. In addition, in 2010, there were about four million testosterone prescriptions written off-label for women, and in primary research doctors tell us they will switch over 90 percent of the off-label use to an FDA approved product.
     
    Q: Investorideas.com
    Several analysts including Rodman & Renshaw have a 12- month price target of $5.00 or more on the stock. The stock has had a 52-wwek high of just over $4.00 and has fallen back… What do you say to that?
     
    A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
    These are very difficult times in the market and in the economy. We believe our stock price is not  reflecting accurately our true value. As we continue to make progress we would expect our stock price to reflect our true value. Happily we are in a very solid cash position with over $73 million in cash as of August 31, 2010 with an approximate $4 million/month burn rate which should decrease to about $3 million/month in 2012.
     
    About LibiGel®
    LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (NYSE:SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time. 
     
    In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity. 
     
    About BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)
    About BioSante Pharmaceuticals, Inc.
    BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.
     
    Forward-Looking Statements
    or revise any forward-looking statement, whether as a result of new information, future events or otherwise. To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to its future operations and products, the timing of anticipated clinical development milestones and regulatory submissions and other statements identified by words such as “will,” “could,” “believes,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “may,” other words of similar meaning, derivatives of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update
     
    For more information, please contact:                                                       
    For Investors:                                                                                      For Media:
    The Trout Group LLC                                                                        Harris D. McKinney, Inc.
    Tricia Swanson                                                                                    Alan Zachary
    (646) 378-2953 tswanson@troutgroup.com                                       (312) 506-5220 azachary@harrisdmckinney.com
     
     
                                  
    About InvestorIdeas.com:
    InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.
     
    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
    Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas
     
    Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.BioSante is a paid advertising biotech stock on Investorideas.com (six thousand five hundred for three months)
     
    Source - Investorideas.com 800-665-0411 -
     
     
    Oct 24 10:32 AM | Link | Comment!
  • Horizontal Drilling Plans for the Mississippian ;( OTCBB: OEDV), (NasdaqGM: RAM), (NYSE: RRC), (NYSE: SD)
    Horizontal Drilling Plans for the Mississippian ;(OTCBB: OEDV), (NasdaqGM: RAM), (NYSE: RRC), (NYSE: SD)
     
    Oil and Gas Companies Announce Drill Plans for Q4 and into 2012
     
    Point Roberts, WA. October 24, 2011 (Investorideas.com Energy Newswire) - www.InvestorIdeas.com, a leader in sector research for independent investors including oil and gas stocks, issues an update on publicly traded oil and gas stocks reporting drilling plans for the Mississippian Formation for the fourth quarter and into 2012.  
     
    Sandridge Energy Inc. (NYSE: SD ) raised investor awareness to the significance of the Mississippian Formation play when it announced in August it entered into a joint venture with an affiliate of Atinum Partners Co., Ltd., an investment firm in the Republic of Korea. According to the agreement, SandRidge will transfer a 13.2% non-operated working interest in approximately 860,000 acres, or approximately 113,000 net acres to Atinum for $500 million.
     
    Osage Exploration and Development, Inc. (OTCBB: OEDV) noted in its Septemberrelease, when the Company also reported an increase in its net acreage to 15,000 acres:“Slawson Exploration as Operator is focused on drilling the project in the fourth quarter this year, yet is bringing a tremendous amount of leadership to the land acquisition process as well. The synergy that has been created by the contribution of U.S. Energy on the land side, coupled with Slawson's and our own efforts, has increased the overall acquisition efficiency dramatically from my perspective," stated Kim Bradford, Chairman and CEO.
     
    Slawson Exploration Company is the Operator of the project and owns 45%, U.S. Energy Development Corporation owns 30%, and Osage Exploration has 25%.
     
    RAM Energy Resources, Inc (NasdaqGM: RAM ) reported in a recent update it is tentatively planning to drill its first horizontal Mississippi well in early 2012. The processing and interpretation of the company's Phase II seismic survey, which covers 31 square miles of the concession to the south and east of the 25 square-mile Phase I survey, is complete. The identification of potential new drilling locations over the Phase II survey is beginning, setting the stage for future drilling.
     
    Range Resources Corporation (NYSE: RRC) reported to shareholders that leasing activity expanded during the quarter in the Mississippian horizontal play of northern Oklahoma. Having started the year with 15,000 net acres, Range's position has increased to over 92,000 net acres. Reserve projections are estimated in the range of 400-500 MBOE per well for approximately 2,000 foot laterals at depths of 5,000 feet. These potential reserves generate attractive finding and development costs, along with strong rates of return in this liquids-rich play. Range's production from the Mississippi horizontal area continues to hold at 3,400 gross (2,709 net) BOE per day. With its larger acreage position, Range is targeting a two rig drilling program in 2012 and is currently focused on adding the necessary infrastructure to facilitate future development
     
    Sandridge Energy Inc. (NYSE: SD ), the most dominant player in theMississippian Play, previously told Investorideas.com, "As far as our drilling plans for 2011, our capital plan has us drilling about 140 producers in the Mississippian.". Sandridge recently sold $231 Million in assets in its East Texas natural gas properties to focus on its core plays including the Mississippian.
    This asset sale is part of the capital plan to execute our 3 Year Strategy of tripling EBITDA, doubling oil production, and lowering our debt ratio by the end of 2014 by continuing to develop high rate of return oil wells in the Central Basin Platform and the Mississippian play in the Mid-Continent."
     
    More about Osage:
    Osage Exploration and Development, Inc. (OTCBB: OEDV)
    Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogotá, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
     
    Follow (OTCBB: OEDV) on Twitter.com
     
    Visit the Osage (OTCBB: OEDV) company showcase profile at Investorideas.com
     
    Request news and trading alerts on OEDV
     
    Research more oil and gas stocks with the oil and gas stock directory at Investorideas.com – lists over 600 stocks including Bakken stocks 
     
    About InvestorIdeas.com:
    InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
     
    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
    Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas
     
     
    Disclaimer: Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
    Disclosure: OEDV is a paid advertising oil and gas company on Investorideas.com - Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
    BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
    Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
     
    800-665-0411 
    Source - Investorideas.com
    Oct 24 10:30 AM | Link | Comment!
  • Junior Oil and Gas Stock Trading Alert: Osage (OTCBB: OEDV) Gaps up 42%
    Junior Oil and Gas Stock Trading Alert: Osage (OTCBB: OEDV) Gaps up 42% 
     
    Point Roberts, WA. October 12, 2011 (Investorideas.com Energy Newswire) - www.InvestorIdeas.com, a leader in sector research including oil and gas stocks, issues a trading alert for Osage Exploration and Development, Inc. (OTCBB: OEDV). The stock is trading at $0.50, up 0.15 (42.86%) on light volume in this morning’s trading session.  
     
    The stock reached its 52 -week high of $0.62 following news of expanding its acreage on the Mississippian project and has pulled back recently to around $0.30 on low volume as oil prices fell. 
     
    The Company reported the following update in September: Osage Exploration and Development, Inc. (OTCBB: OEDV), along with its partners Slawson Exploration Company and U.S. Energy Development Corporation, is pleased to announce that we have been able to continue to increase our net land position to 15,000 acres in the highly prospective area east of the Nemaha Ridge in the Oklahoma horizontal Mississippian play.
     
    Slawson Exploration Company is the Operator of the project and owns 45%, U.S. Energy Development Corporation owns 30%, and Osage Exploration has 25%.
     
     
     
     
    Osage Exploration and Development, Inc. (OTCBB: OEDV)
     
    Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogotá, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
     
    Follow (OTCBB: OEDV) on Twitter.com
     
    Visit the Osage (OTCBB: OEDV) company showcase profile at Investorideas.com
     
    Request news and trading alerts on OEDV
     
    Research more oil and gas stocks with the oil and gas stock directory at Investorideas.com – lists over 600 stocks including Bakken stocks 
     
    About InvestorIdeas.com:
    InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
     
    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
    Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas
     
     
    Disclaimer: Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
    Disclosure: OEDV is a paid advertising oil and gas company on Investorideas.com - Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
    BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
    Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
     
    800-665-0411 - cvanzant@investorideas.com or dawn@investorideas.com
    Source - Investorideas.com
     
                                             
     
     
     
     
     
     
     
    Oct 12 1:24 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.